News Eisai: UK gives pharma a poor deal, may invest elsewhere Japanese pharma getting frustrated with NICE
News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
News NICE backs funding for Pfizer, Novartis breast cancer drugs Pfizer had been giving drug free to NHS before decision
News NICE to play key role in UK drug fast-track scheme Former GSK CEO Sir Andrew Witty will oversee proceedings.
News Roche's Tecentriq gets three years to prove itself on Cancer... Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.
News FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
